1 Market Overview of Treatment for Syndromes of Progressive Ataxia and Weakness Disorders 1.1 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Overview 1.1.1 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Product Scope 1.1.2 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Status and Outlook 1.2 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Region (2016-2027) 1.4 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Historic Market Size by Region (2016-2021) 1.5 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size Forecast by Region (2022-2027) 1.6 Key Regions, Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) 1.6.1 North America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) 1.6.2 Europe Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) 1.6.3 Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) 1.6.4 Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) 1.6.5 Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) 2 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Overview by Type 2.1 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Historic Market Size by Type (2016-2021) 2.3 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size by Type (2022-2027) 2.4 Monoclonal Antibody 2.5 Small Molecule Technologies 3 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Overview by Application 3.1 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Historic Market Size by Application (2016-2021) 3.3 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size by Application (2022-2027) 3.4 Friedreich's ataxia 3.5 Hereditary neuropathies 3.6 Machado Joseph disease 3.7 Progressive bulbar palsy and multiple sclerosis 3.8 Other 4 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Competition Analysis by Players 4.1 Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders as of 2020) 4.3 Date of Key Players Enter into Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market 4.4 Global Top Players Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Headquarters and Area Served 4.5 Key Players Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Product Solution and Service 4.6 Competitive Status 4.6.1 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Acorda Therapeutics 5.1.1 Acorda Therapeutics Profile 5.1.2 Acorda Therapeutics Main Business 5.1.3 Acorda Therapeutics Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.1.4 Acorda Therapeutics Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.1.5 Acorda Therapeutics Recent Developments 5.2 Cadila Healthcare 5.2.1 Cadila Healthcare Profile 5.2.2 Cadila Healthcare Main Business 5.2.3 Cadila Healthcare Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.2.4 Cadila Healthcare Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.2.5 Cadila Healthcare Recent Developments 5.3 American Regent 5.5.1 American Regent Profile 5.3.2 American Regent Main Business 5.3.3 American Regent Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.3.4 American Regent Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.3.5 Dr. Reddy Laboratories Recent Developments 5.4 Dr. Reddy Laboratories 5.4.1 Dr. Reddy Laboratories Profile 5.4.2 Dr. Reddy Laboratories Main Business 5.4.3 Dr. Reddy Laboratories Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.4.4 Dr. Reddy Laboratories Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.4.5 Dr. Reddy Laboratories Recent Developments 5.5 Sanofi 5.5.1 Sanofi Profile 5.5.2 Sanofi Main Business 5.5.3 Sanofi Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.5.4 Sanofi Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.5.5 Sanofi Recent Developments 5.6 Baxter International 5.6.1 Baxter International Profile 5.6.2 Baxter International Main Business 5.6.3 Baxter International Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.6.4 Baxter International Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.6.5 Baxter International Recent Developments 5.7 Pfizer 5.7.1 Pfizer Profile 5.7.2 Pfizer Main Business 5.7.3 Pfizer Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.7.4 Pfizer Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.7.5 Pfizer Recent Developments 5.8 Novartis AG 5.8.1 Novartis AG Profile 5.8.2 Novartis AG Main Business 5.8.3 Novartis AG Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.8.4 Novartis AG Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.8.5 Novartis AG Recent Developments 5.9 Abbott Laboratories 5.9.1 Abbott Laboratories Profile 5.9.2 Abbott Laboratories Main Business 5.9.3 Abbott Laboratories Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.9.4 Abbott Laboratories Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.9.5 Abbott Laboratories Recent Developments 5.10 Bristol-Myers Squibb 5.10.1 Bristol-Myers Squibb Profile 5.10.2 Bristol-Myers Squibb Main Business 5.10.3 Bristol-Myers Squibb Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.10.4 Bristol-Myers Squibb Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.10.5 Bristol-Myers Squibb Recent Developments 5.11 Biogen Idec. 5.11.1 Biogen Idec. Profile 5.11.2 Biogen Idec. Main Business 5.11.3 Biogen Idec. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.11.4 Biogen Idec. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.11.5 Biogen Idec. Recent Developments 5.12 Eli Lilly and Company 5.12.1 Eli Lilly and Company Profile 5.12.2 Eli Lilly and Company Main Business 5.12.3 Eli Lilly and Company Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.12.4 Eli Lilly and Company Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.12.5 Eli Lilly and Company Recent Developments 5.13 Roche Holding Ltd 5.13.1 Roche Holding Ltd Profile 5.13.2 Roche Holding Ltd Main Business 5.13.3 Roche Holding Ltd Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions 5.13.4 Roche Holding Ltd Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) & (2016-2021) 5.13.5 Roche Holding Ltd Recent Developments 6 North America 6.1 North America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Dynamics 11.1 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Industry Trends 11.2 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Drivers 11.3 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Challenges 11.4 Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Region (2016-2021) & (US$ Million) Table 3. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size Share by Region (2016-2021) Table 4. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size Share by Region (2022-2027) Table 6. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Type (2016-2021) & (US$ Million) Table 8. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue Market Share by Type (2016-2021) Table 9. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue Market Share by Type (2022-2027) Table 11. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Application (2016-2021) & (US$ Million) Table 13. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue Market Share by Application (2016-2021) Table 14. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue Market Share by Application (2022-2027) Table 16. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue (US$ Million) by Players (2016-2021) Table 17. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders as of 2020) Table 19. Date of Key Manufacturers Enter into Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Table 20. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Top Players Headquarters and Area Served Table 21. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Product Solution and Service Table 22. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Acorda Therapeutics Basic Information List Table 25. Acorda Therapeutics Description and Business Overview Table 26. Acorda Therapeutics Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 27. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Acorda Therapeutics (2016-2021) Table 28. Acorda Therapeutics Recent Developments Table 29. Cadila Healthcare Basic Information List Table 30. Cadila Healthcare Description and Business Overview Table 31. Cadila Healthcare Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 32. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Cadila Healthcare (2016-2021) Table 33. Cadila Healthcare Recent Developments Table 34. American Regent Basic Information List Table 35. American Regent Description and Business Overview Table 36. American Regent Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 37. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of American Regent (2016-2021) Table 38. American Regent Recent Developments Table 39. Dr. Reddy Laboratories Basic Information List Table 40. Dr. Reddy Laboratories Description and Business Overview Table 41. Dr. Reddy Laboratories Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 42. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Dr. Reddy Laboratories (2016-2021) Table 43. Dr. Reddy Laboratories Recent Developments Table 44. Sanofi Basic Information List Table 45. Sanofi Description and Business Overview Table 46. Sanofi Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 47. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Sanofi (2016-2021) Table 48. Sanofi Recent Developments Table 49. Baxter International Basic Information List Table 50. Baxter International Description and Business Overview Table 51. Baxter International Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 52. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Baxter International (2016-2021) Table 53. Baxter International Recent Developments Table 54. Pfizer Basic Information List Table 55. Pfizer Description and Business Overview Table 56. Pfizer Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 57. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Pfizer (2016-2021) Table 58. Pfizer Recent Developments Table 59. Novartis AG Basic Information List Table 60. Novartis AG Description and Business Overview Table 61. Novartis AG Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 62. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Novartis AG (2016-2021) Table 63. Novartis AG Recent Developments Table 64. Abbott Laboratories Basic Information List Table 65. Abbott Laboratories Description and Business Overview Table 66. Abbott Laboratories Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 67. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Abbott Laboratories (2016-2021) Table 68. Abbott Laboratories Recent Developments Table 69. Bristol-Myers Squibb Basic Information List Table 70. Bristol-Myers Squibb Description and Business Overview Table 71. Bristol-Myers Squibb Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 72. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Bristol-Myers Squibb (2016-2021) Table 73. Bristol-Myers Squibb Recent Developments Table 74. Biogen Idec. Basic Information List Table 75. Biogen Idec. Description and Business Overview Table 76. Biogen Idec. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 77. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Biogen Idec. (2016-2021) Table 78. Biogen Idec. Recent Developments Table 79. Eli Lilly and Company Basic Information List Table 80. Eli Lilly and Company Description and Business Overview Table 81. Eli Lilly and Company Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 82. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Eli Lilly and Company (2016-2021) Table 83. Eli Lilly and Company Recent Developments Table 84. Roche Holding Ltd Basic Information List Table 85. Roche Holding Ltd Description and Business Overview Table 86. Roche Holding Ltd Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Products, Services and Solutions Table 87. Revenue (US$ Million) in Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Business of Roche Holding Ltd (2016-2021) Table 88. Roche Holding Ltd Recent Developments Table 89. North America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2021) & (US$ Million) Table 90. North America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2022-2027) & (US$ Million) Table 91. Europe Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2021) & (US$ Million) Table 92. Europe Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2022-2027) & (US$ Million) Table 93. Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Region (2016-2021) & (US$ Million) Table 94. Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Region (2022-2027) & (US$ Million) Table 95. Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Region (2016-2021) Table 96. Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Region (2022-2027) Table 97. Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2016-2021) & (US$ Million) Table 98. Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2022-2027) & (US$ Million) Table 99. Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Players (2016-2021) & (US$ Million) Table 100. Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size by Country (2022-2027) & (US$ Million) Table 101. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Trends Table 102. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Drivers Table 103. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Challenges Table 104. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Restraints Table 105. Research Programs/Design for This Report Table 106. Key Data Information from Secondary Sources Table 107. Key Data Information from Primary Sources List of Figures Figure 1. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Regions: 2021 VS 2027 Figure 4. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Forecasted Market Size Share by Region (2022-2027) Figure 5. North America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size Share by Type in 2021 & 2027 Figure 11. Monoclonal Antibody Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Small Molecule Technologies Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size Share by Application in 2021 & 2027 Figure 14. Friedreich's ataxia Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Hereditary neuropathies Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Machado Joseph disease Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. Progressive bulbar palsy and multiple sclerosis Market Size (US$ Million) YoY Growth (2016-2027) Figure 18. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 19. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 20. Global Top 5 and Top 10 Players Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share in 2020 Figure 21. North America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Country (2016-2027) Figure 22. United States Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 23. Canada Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 24. Germany Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 25. France Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 26. U.K. Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 27. Italy Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 28. Russia Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 29. Nordic Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 30. Rest of Europe Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 31. Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Region (2016-2027) Figure 32. China Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 33. Japan Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 34. South Korea Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 35. Southeast Asia Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 36. India Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 37. Australia Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 38. Rest of Asia-Pacific Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 39. Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Country (2016-2027) Figure 40. Mexico Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 41. Brazil Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 42. Rest of Latin America Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 43. Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Share by Country (2016-2027) Figure 44. Turkey Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 45. Saudi Arabia Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 46. UAE Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 47. Rest of Middle East & Africa Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size (2016-2027) & (US$ Million) Figure 48. Bottom-up and Top-down Approaches for This Report Figure 49. Data Triangulation

Acorda Therapeutics Cadila Healthcare American Regent Dr. Reddy Laboratories Sanofi Baxter International Pfizer Novartis AG Abbott Laboratories Bristol-Myers Squibb Biogen Idec. Eli Lilly and Company Roche Holding Ltd